{"classes":[{"categories":[{"measurements":[{"comment":"NA: not reached","groupId":"OG000","lowerLimit":"19.3","upperLimit":"NA","value":"NA"},{"comment":"NA: not reached","groupId":"OG001","lowerLimit":"19.6","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"154"}],"units":"Participants"}],"description":"Progression-free survival (PFS) is defined as the interval from randomization to the first documentation of definitive disease progression or death from any cause. Definitive disease progression is CLL progression based on standard criteria, excluding lymphocytosis alone. PFS was to be assessed by an independent review committee (IRC).","dispersionType":"95% Confidence Interval","groups":[{"description":"Idelalisib (Zydelig®) 150 mg tablet twice daily + bendamustine intravenously (starting dose of 90 mg/m\\^2 for up to 6 total cycles) + rituximab (375 mg/m\\^2 on Day 1 and 500 mg/m\\^2 thereafter for at total of 6 infusions)","id":"OG000","title":"Idelalisib+Bendamustine+Rituximab"},{"description":"Placebo tablet twice daily + bendamustine intravenously (starting dose of 90 mg/m\\^2 for up to 6 total cycles) + rituximab intravenously (375 mg/m\\^2 on Day 1 and 500 mg/m\\^2 thereafter for at total of 6 infusions)","id":"OG001","title":"Placebo+Bendamustine+Rituximab"}],"paramType":"MEDIAN","populationDescription":"Intent to Treat (ITT) analysis set: all participants who are randomized in the study with treatment group designated according to initial randomization.\n\nDue to early study termination, the prespecified efficacy analyses were not conducted. The PFS data presented are investigator assessments rather than IRC assessments.","reportingStatus":"POSTED","timeFrame":"Up to 22 months","title":"Progression-Free Survival","type":"PRIMARY","unitOfMeasure":"months"}